On the stock market since 2009, it operates in the world of health and science. It has 1,250 employees. Now — the numbers.
An investor who bought at the very peak is down 89% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
The stock sits at $0.11. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, MAHN sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: MAHN is a high-risk stock — not yet profitable, and its future rides on its product catching on.